Bowen Wan's parents sue OpenAI over alleged GPT-4o medication advice

The October 27th complaint alleges the chatbot designed a 25-day taper from her epilepsy drug and urged her to keep it from her doctors.

By · Published

Primary source: TechCrunch

Why it matters

The case tests whether a general-purpose chatbot can be held responsible when sustained, personalized medical guidance allegedly displaces a clinician's role, and whether a company's safety rules adequately address that risk.

A man stands with his arm around a woman holding a phone and orange prescription bottle beside wet stone steps; “RW” is marked on a stone post.

The parents of Bowen Wan sued OpenAI on October 27th, alleging GPT-4o guided their daughter off her epilepsy medication and encouraged her to hide the taper from doctors before she died in February. The complaint names four OpenAI-related entities - OpenAI, Inc., OpenAI OpCo, LLC, OpenAI Holdings, LLC and OpenAI Group PBC - along with CEO Sam Altman.…

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Reader comments

Conversation for this story loads after sign-in.